GAITHERSBURG, Md., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference. Details are as follows:

 Conference:Guggenheim SMID Cap Biotech Conference
   
 Date/Time:Wednesday, February 5, 2025, at 9:30 a.m. EST
   
The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn

Get the latest news
delivered to your inbox
Sign up for The Manila Times newsletters
By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.

Follow @AltimmuneInc on Twitter

Company Contact:

Greg Weaver

Chief Financial Officer

Phone: 240-654-1450

[email protected]

Investor Contact:

Lee Roth

Burns McClellan

Phone: 646-382-3403

[email protected]

Media Contact:

Danielle Cantey

Inizio Evoke, Biotech

Phone: 619-826-4657

[email protected]